MedWatch

Biogen upgrades financial guidance after exceeding expectations in Q2

Halfway through the accounting year, Biogen predicts a higher revenue than previously expected.

Photo: BRIAN SNYDER/REUTERS / X90051

US firm Biogen has upgraded its guidance for the financial year and now predicts a higher revenue than originally expected, Bloomberg News writes based on the company's Q2 report.

The pharmaceutical company now predicts a revenue of between USD 10.65bn and USD 10.85bn, compared to its previous expectation of between USD 10.45bn and USD 10.75bn. The analyst consensus estimate was a USD 10.59bn revenue.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs